biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Gene Therapies

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Aug 31, 2022 4:59pm

161 Views

Post# 34933727

RE:RE:RE:RE:Gene Therapies

Pof, do you really think that IND status for one LSD enzyme replacement therapy is worth $225 million with $15 million up front compared to $138 million and $3 million for four LSD enzyme replacement therapies? You do realize that there is no R&D to do for these ERTs, that the LSDs are well studied and the enzymes are known for them all.

Of all the programs that Bioasis has developed you continue to pick LSDs as your big deal when they're the most worthless of all of those programs. Why do ya think Bioasis sold them so cheaply?

jd

<< Previous

Bullboard Posts

Next >>

Geologica Resource: Polymetallic upside at a depressed price